Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Nktx | Mind Blowing Facts

34 Stocks Moving In Monday's Mid-Day Session

Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose finding studies of its two lead chimeric antigen receptor natural killer cell therapy candidates, NKX101 and NKX019.

Benzinga · Apr 25, 2022

Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses

Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses

Nkarta Inc (NASDAQ:NKTX) has revealed the first human results from its two lead off-the-shelf NK cell therapies, with the high-dose regimens exhibiting multiple complete responses in blood cancer patients. For NKX101, three patients achieved a complete response (CR) among five AML patients who received three doses of either 1 billion or 1.5 billion…

Benzinga · Apr 25, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play